GW Pharma (GWPH) Tops Q3 EPS by 103c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Reiterates Bullish View on GW Pharma (GWPH) Post Q3; Says All Eyes on Epilepsy Pivotal Data In Early Q1:16
August 6, 2015 1:30 PM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and $135 price target on GW Pharma (NASDAQ: GWPH) following Q3 results although all eyes are on the epilepsy pivotal data in early Q1 2016.
Nadeau commented, "GW remains well funded with £254MMin cash at the... More
GW Pharma (GWPH) Announces Receipt of FDA Fast-Track Designation for CBD as NHIE Treatment
August 6, 2015 6:46 AM EDTGW Pharma (NASDAQ: GWPH) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy, or NHIE. In addition, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE, for which GW has already received Orphan Drug Designation from the FDA. There are currently no approved medicines in Europe or the U.S. specifically indicated for NHIE or perinatal... More
